Exicure Inc (XCUR)
$2.7
Performance
- $2.70$2.82$2.70
0.0%
Downside
Day's Volatility :4.25%
Upside
4.25%
- $1.44$6.00$2.70
46.67%
Downside
52 Weeks Volatility :76.0%
Upside
55.0%
Returns
| Period | Exicure Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 83.87% | 0.0% |
6 Months | -1.07% | 0.0% |
1 Year | -24.11% | 0.0% |
3 Years | -98.52% | -20.2% |
Highlights
Market Capitalization | 6.0M |
Book Value | $0.93 |
Earnings Per Share (EPS) | -4.5 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1193.2% |
Return On Assets TTM | -26.41% |
Return On Equity TTM | -144.41% |
Revenue TTM | 500.0K |
Revenue Per Share TTM | 0.29 |
Quarterly Revenue Growth YOY | 927.9999999999999% |
Gross Profit TTM | 9.1M |
EBITDA | -5.8M |
Diluted Eps TTM | -4.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 25.93%
Technicals Summary
Sell
Neutral
Buy
Exicure Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Exicure Inc | 56.5% | -1.07% | -24.11% | -98.52% | -99.23% |
 Regeneron Pharmaceuticals, Inc. | -13.97% | 8.28% | 24.49% | 82.67% | 258.6% |
 Novo Nordisk A/s | -14.46% | -7.16% | 29.25% | 137.43% | 348.48% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 77.93% | 59.32% | 38.21% | 249.95% |
 Vertex Pharmaceuticals Incorporated | -5.23% | 12.26% | 28.5% | 155.67% | 163.05% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Exicure Inc | 0.19 | NA | NA | 0.0 | -1.44 | -0.26 | NA | 0.93 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Exicure Inc | Sell | $6.0M | -99.23% | 0.19 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 258.6% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 348.48% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 249.95% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.05% | 32.84 | -4.74% |
Insights on Exicure Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 21.77M → 500.0K (in $), with an average decrease of 84.2% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -5.76M → -600.0K (in $), with an average increase of 95.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 83.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 136.7%
Institutional Holdings
The Carlyle Group Inc
3.26%Geode Capital Management, LLC
0.65%Northwestern University
0.60%Susquehanna International Group, LLP
0.53%Vanguard Group Inc
0.46%UBS Group AG
0.20%
Company Information
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Organization | Exicure Inc |
Employees | 5 |
CEO | Mr. Paul Kang |
Industry | Miscellaneous Commercial Services |
Discover More
Eagle Pharmaceuticals Inc.
$2.70
-2.53%
Rumbleon Inc
$2.70
-2.53%
Olaplex Holdings, Inc.
$2.70
-2.53%
Bluebird Bio, Inc.
$2.70
-2.53%
Generation Income Properties Inc
$2.70
-2.53%
Ondas Holdings Inc
$2.70
-2.53%
Nuveen Credit Strat Incm
$2.70
-2.53%
Touchstone Climate Transition Etf
$2.70
-2.53%
Atlas Lithium Corp
$2.70
-2.53%